Human Molecular Genetics Advance Access published online on May 22, 2006
Human Molecular Genetics, doi:10.1093/hmg/ddl136
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Carcinogenesis, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Molecular Pathophysiology, Tokyo Medical and Dental University, Tokyo, Japan
* To whom correspondence should be addressed. Ewing's family tumors (EFTs) are highly malignant tumors arising from bone and soft tissues that exhibit EWS-FLI1 or variant EWS-ETS gene fusions in more than 85% of the cases. We show here that CIC, a human homologue of Drosophila capicua which encodes an HMG-box transcription factor, is fused to a double homeodomain gene DUX4 as a result of a recurrent chromosomal translocation t(4;19)(q35;q13). This translocation was seen in two cases of soft tissue sarcoma diagnosed as Ewing-like sarcoma. CIC-DUX4 exhibits a transforming potential for NIH 3T3 fibroblasts, and as a consequence of fusion with a C-terminal fragment of DUX4 CIC acquires an enhanced transcriptional activity, suggesting that expression of its downstream targets might be deregulated. Gene expression analysis identified the ETS family genes, ERM/ETV5 and ETV1, as potential targets for the gene product of CIC-DUX4. Indeed, CIC-DUX4 directly binds the ERM promoter by recognizing a novel target sequence and significantly up-regulates its expression. This study clarifies the function of CIC and its role in tumorigenesis, as well as the importance of the PEA3 subclass of ETS family proteins in the development of EFTs arising through mechanisms different from those involving EWS-ETS chimeras. Moreover, the study identifies the role of DUX4 that is closely linked to fascioscapulohumeral muscular dystrophy (FSHD) in transcriptional regulation.
Received February 5, 2006
Revised May 18, 2006
Accepted May 18, 2006
Article
Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation
Miho Kawamura-Saito 1,
Yukari Yamazaki 2,
Keiko Kaneko 1,
Noriyoshi Kawaguchi 3,
Hiroaki Kanda 4,
Hiroyuki Mukai 5,
Takahiro Gotoh 6,
Tohru Motoi 7,
Masashi Fukayama 7,
Hiroyuki Aburatani 8,
Toichiro Takizawa 9,
and
Takuro Nakamura 10 *
2 Department of Carcinogenesis, Japanese Foundation for Cancer Research, Tokyo, Japan
3 Department of Orthopaedic Oncology, Japanese Foundation for Cancer Research, Tokyo, Japan
4 Department of Pathology, Japanese Foundation for Cancer Research, Tokyo, Japan
5 FML Laboratory, Tokyo, Japan
6 Department of Orthopedic Surgery, Komagome Hospital, Tokyo, Japan
7 Department of Pathology, University of Tokyo Hospital, Tokyo, Japan
8 Genome Research Division, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan
9 Department of Molecular Pathophysiology, Tokyo Medical and Dental University, Tokyo, Japan
10 Department of Carcinogenesis, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan
Takuro Nakamura, E-mail: takuro-ind{at}umin.net
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. L. Ordonez, D. Osuna, D. Herrero, E. de Alava, and J. Madoz-Gurpide Advances in Ewing's Sarcoma Research: Where Are We Now and What Lies Ahead? Cancer Res., September 15, 2009; 69(18): 7140 - 7150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, R. Bhargava, T. Zheng, L. Wexler, M. H. Collins, D. Roulston, and M. Ladanyi Undifferentiated Small Round Cell Sarcomas with Rare EWS Gene Fusions: Identification of a Novel EWS-SP3 Fusion and of Additional Cases with the EWS-ETV1 and EWS-FEV Fusions J. Mol. Diagn., September 1, 2007; 9(4): 498 - 509. [Abstract] [Full Text] [PDF]
|
|